Purpose: Ultrasound-guided core needle biopsy (US CNB) is increasingly used in the histologic evaluation of non-palpable solid breast lesions. We retrospectively investigated the diagnostic accuracy of this technique, using an 18-gauge needle in 422 nonpalpable breast lesions. Materials and Methods: 583 female patients with an average age of 56 (range, 22 90) years underwent 590 US CNBs. Between January 1994 and December 1999, using 18-gauge needles, an average of four cores per lesion was obtained. Three hundred and eighty-five lesions were subsequently surgically excised; for 14 of these, the pathologic diagnosis was breast carcinoma metastasis, while 23 with benign diagnoses were clinically followed up for 2.5 years and were considered for analysis. Results: Of the 422 lesions, 340 (80.6%) were malignant [308 invasive, 24 ductal carcinoma in situ (DCIS), 7 DCIS with undetermined invasion and 1 DCIS vs. lobular carcinoma in situ], 67 (15.9%) were benign [30 fibroadenoma (FA) and 37 other diagnoses], and five (1.2%) were fibroepithelial lesions. The remaining ten samples (2.4%) included six cases of atypical ductal hyperplasia (ADH), two of atypical hyperplasia (AH), and two of lobular neoplasia. The sensitivity, specificity, positive predictive value, and negative predictive value of CNBs were 99%, 100%, 100%, and 96%, respectively. Two cases of invasive carcinoma were missed at CNB; there was no false-positive diagnosis. Five of six ADHs and one of two AHs were found to be carcinomas (3 DCIS and 3 infiltrating duct carcinomas). Sixteen of 24 (66.7%) cases of DCIS were found at excision to be invasive carcinomas. Of 31 FAs, two (6.5%) were found to be low-grade phyllodes tumor (PT). The five fibroepithelial lesions were shown at excision to be either PT (n=4) or FA (n=1). Conclusion: US CNB using an 18-gauge needle is a safe and reliable means of diagnosing breast carcinoma. Because of the high prevalence of ductal carcinoma in these lesions; findings of ADH/AH at US CNB indicate that surgical excision is needed. In order to rule out low-grade PT, a diagnosis of FA at CNB requires close follow-up.
The increased detection of non-palpable breast lesions at screening mammography has resulted in the growing use of image-guided core needle biopsies (CNB). Imaging modalities used in CNB of breast lesions include stereotactic mammography, ultrasound (US) and MRI (1, 2) . With advancements in ultrasound technology, more than 90% of mammographically detected, nonpalpable breast masses are identified in this way (3, 4) . The target of US CNB is solid breast masses, which account for two-thirds of non-palpable breast lesions detected by screening mammography (5) . US CNB is becoming the first-line guidance technique for CNB in the evaluation of non-palpable solid breast lesions. It can be applied to virtually any mass visualized at sonography, including lesions with inconclusive findings at fine needle aspiration (FNA), and for obtaining histologic confirmation of carcinoma in order to implement subsequent therapy including preoperative chemotherapy and/or a definitive, one-stage surgical procedure. The advantages of US over stereotactically guided CNB for mass lesions include its relative ease of use (even at the initial visit) and lack of roentgenographic exposure (2, 6) . The role of US CNB becomes critical in the diagnosis of lesions not seen on mammograms, such as those in a radiodense breast or at the periphery of the breast close to the chest wall.
Stereotactic CNB is now primarily applied in the biopsy of lesions with suspicious calcification and masses not identified at sonography. Whereas image-guided CNBs have been extensively studied, most reports have focused on stereotactic CNB, and US CNB alone has rarely been focused on (6, 7) . Due to differences between the features of US and stereotactic imaging, the diagnostic accuracy of these two modalities in the imaging of breast lesions should be studied separately (8) . With the aim of reducing possible complications, including local hemorrhage, discomfort and tumor seeding along the needle track, an 18-gauge needle is used for US CNB. It has been reported that the risk of complications correlates with the size of needle used (9 11) , and though a smaller (18-gauge) needle is in this respect advantageous, reports have claimed that for CNB diagnosis, a large needle (14-, or 16-gauge) is more accurate (12, 13) .
Using an 18-gauge needle, we retrospectively studied the diagnostic accuracy of US CNB of 422 non-palpable breast lesions.
Materials and Methods
Between January 1994 and December 1999, 583 patients with 590 breast masses visualized at sonography underwent US CNB using an 18-gauge needle. To confirm that biopsy was indicated, the mammograms were systematically reviewed by an experienced radiologist using standard criteria (14) . From 1998, a Mammotome device was used, and for most solid breast lesions with microcalcifications, US CNB was not indicated. CNB was performed by radiologists under direct visualization using a handheld, high frequency (7.5 mHz) linear-array transducer. A spring-loaded biopsy gun with an 18-gauge needle was applied and CNB was repeated in different areas of a tumor until a sufficient number of satisfactory cores (average, four per lesion) were obtained. These were placed in 10% formaline solution and sent for routine processing. Six tissue sections per core, with the first and the last stained with H&E, were obtained and examined by breast pathologists.
The histologic diagnoses of CNB specimens were categorized according to the lesion type: 1) malignant neoplasms [invasive carcinoma, ductal carcinoma in situ (DCIS) with undetermined invasion, and DCIS]; 2) atypical ductal hyperplasia (ADH)/atypical hyperplasia (AH; ADH could not be excluded) (ADH/AH); 3) lobular neoplasia [atypical lobular hyperplasia (ALH) or lobular carcinoma in situ (LCIS)]; 4) fibroepithelial lesions [phyllodes tumor (PT) vs. fibroadenoma (FA)]; and 5) benign lesions (specific types or not otherwise specified).
CNB findings were confirmed on the basis of subsequent tissue excision (n=385); the presence of metastases, confirmed by pathologic examination (n=14) and clinical follow-up by mammography for at least 2.5 years (n=23). The diagnostic outcomes of US CNB were correlated with the follow-up findings. Sensitivity, specificity, and positive and negative predictive value were calculated. Six cases diagnosed at CNB as ADH and two as AH were excluded from the calculation.
Results
The diagnostic results of 590 US CNBs are summarized in Table 1 . Using an 18-gauge needle, sufficient specimens for adequate diagnosis were obtained. Rebiopsy due to sampling inadequacy was required in only 3 cases (0.5%).
Confirmation was available for 422/590 CNBs (71.5%) ( Table 1 ). The pathological findings of US CNB were divided into five groups, as follows: Table 2 summarizes the subsequent confirmative findings of cases in which malignant neoplasms were diagnosed at US CNB. Among 340 cases, there were 308 invasive carcinomas, seven DCIS with undetermined invasion, 24 DCIS, and one DCIS vs. LCIS. Among invasive carcinoma patients, 294 underwent subsequent breast surgery, at which time the condition was confirmed in 279 cases. DCIS only was found in six cases, and in the other eight, no residual tumor was identified. The 14 patients with DCIS, or in whom subsequently obtained surgical specimens revealed no residual tumor, underwent preoperative chemotherapy for inflammatory carcinoma (n=1) or their masses were visualized at mammography/sonography (n=13). After chemotherapy, there was either no evidence of a tumor, or preoperative mammography/sonography revealed that a small residual tumor was present. In one case, the lesions seen at initial diagnosis were small and clinically non-palpable, and ultrasound showed that two measured 1.3 cm and 0.6 cm, respectively. The diagnosis at US CNB was invasive lobular carcinoma (ILC), and the subsequent surgical specimen indicated DCIS without a residual invasive component.
Malignant neoplasia
Concurrent or subsequent FNA or extramammary surgical biopsy/excision revealed metastases in 14 of 308 cases, with a US CNB diagnosis of invasive carcinoma. All these patients underwent preoperative chemotherapy.
Among seven cases diagnosed as DCIS with undetermined invasion, invasive carcinoma was found at surgical excision in six (85.7%). Among 24 cases diagnosed as DCIS, invasive carcinoma was found in 16 (66.7%). Six of these had an invasive component measuring 5 mm; in four, the size of this was (1 mm. Analysis of the subsequent surgical specimen of DCIS vs. LCIS showed that ILC was present.
ADH/AH
At US CNB, six cases of ADH and two of AH were diagnosed. Subsequent surgery revealed that five (83%) of the six supposed ADH cases and one of the two thought to be AH were in fact carcinomas (3 DCIS, and 3 IDC with extensive DCIS component). Malignant neoplasms thus accounted for 75% of CNBs diagnosed as ADH/ AH.
Lobular neoplasia
One of the two cases diagnosed at US CNB as lobular neoplasia (ALH or LCIS) was found at excision to be invasive lobular carcinoma. Examination of the surgical specimen revealed that the tumor was the classic type and that the invasive area measured 0.4 cm in its greatest dimension (0.9 cm at ultrasound).
Fibroepithelial lesions
Five fibroepithelial lesions were diagnosed at CNB. Four were found at surgical excision to be PT and the other was FA. Two of the PTs were of undetermined malignant potential and one was benign. Table 3 summarizes the follow-up results of US CNB at which diagnoses were benign. Eighteen of 31 fibroadenomas were surgically excised and 13 were followed-up mammagraphically for 2.5 years or longer. Excisional biopsy showed that two (underestimation rate, 6.5%) were phyllodes tumor (one of undetermined malignant potential and one benign). Surgical excision of the former revealed the presence of a hyalinized benign component in more than 60% of the lesion, though US 355 CNB had not indicated this (sampling problem). In neither of the two PTs did CNB revealed the characteristic leaf-like pattern.
Benign lesions
In this last group, there was a false negative case. At mammography, the lesion appeared as microcalcifications only, without a mass; ultrasound examination confirmed the absence of a mass, though a vague elongated hypoechoic area was present. Five US CNBs were obtained from this patient, and duct dilatation with mild epithelial hyperplasia and calcification was observed. Subsequent needle localization excision revealed an invasive, moderately differentiated ductal carcinoma, 5 mm in diameter.
The overall sensitivity, specificity, positive predictive value, and negative predictive value of US CNBs in this study were 99%, 100%, 100%, and 96%, respectively. Two cases of invasive carcinoma were missed at CNB. There was no false-positive diagnosis.
Discussion
Due to its reliability, lower cost, and lower rates of morbidity and subsequent scarring, core needle biopsy has achieved an established role in reducing the number 356 of excisional biopsies (15, 16) . CNB provides more specific histologic diagnosis than fine needle aspiration, especially for lesions which are difficult to aspirate or where problems arise in determining tumor invasiveness.
A number of studies have revealed high concordance between CNB using 14-gauge needles and surgical diagnoses of breast palpable and non-palpable solid breast lesions, especially in carcinoma cases (6, 7, 17, 18) . No false-positive diagnosis of malignancy has been reported, though a low false-negative rate ( 1.7%) did occur (19, 20) . Diagnostic sensitivity varied according to needle size. Nath et al. showed that for the diagnosis of malignant lesions, sensitivity was 100%, 92%, and 65% for 14-, 16-, and 18-gauge needles, respectively, and that although sensitivity for benign diseases was 100% for all three needle sizes, the number of specific benign diagnoses increased with size (13). For 18-gauge needles, their result was poorer than in the present study, a finding which might be explained by the fact that they used short-throw needles, known to harvest significantly less tissue than long-throw needles and for that reason recommended only occasionally. Using stereotactic CNB and US CNB with 14-gauge needles, Nguyen et al. achieved a sensitivity of 99% in the diagnosis of breast lesions which were confirmed on the basis of surgery or clinical follow-up (19) . Specificity for the diagnosis of breast lesions on the basis of image-guided CNB findings has consistently been 100% in all studies (13, 19, 20) .
The decision to perform breast biopsy with larger needles was based on the assumption that breast tissue obtained with smaller needles is frequently friable and tends to fragment more often than tissue harvested with 14-gauge needles. However, the results of our study for diagnosing non-palpable solid breast lesions using US 18-gauge CNB show a diagnostic accuracy comparable to that noted in studies in which 14-gauge needles were used. A suggestion supported by our findings is that lesions in which mammography reveals the presence of microcalcifications frequently consist of friable and fatty tissue (12, 21, 22) , both of which are believed to be responsible for incorrect diagnosis with smaller needles (12, 21) . We found that was much higher than in earlier reports, and that sensitivity was as high as when larger needles were used. Since 1998, US CNB using an 18-gauge needle has not been indicated in most cases involving lesions with microcalcifications. In such cases, larger needles or a Mammotome device have been used.
Our study also highlights three situations that warrant careful evaluation, as discussed below. First, for lesions visualized at sonography there was no false-positive diagnosis of invasive carcinoma at US CNB. Two cases of invasive carcinoma were, however, missed at US CNB (0.8% false-negative rate). In both, surgical specimens measured 0.4 cm in their greatest dimension, and were not visualized at sonography. Ultrasound is reported to be less accurate for the detection of lesions smaller than 0.6 cm, though mammography-directed US can visualize the overwhelming majority of non-palpable masses detected at mammography (1, 7) . It is therefore recommended that stereotactic mammography should be the preferred method of localization and/or biopsy for most lesions 5 mm.
For 16 (67%) of 24 lesions diagnosed as DCIS on the basis of US CNB findings, proof of invasion was provided by the excisional specimen. This prevalence appears higher than that reported in the literature (range, 16 23%; mean, 19%) (18, 19, 23 25) , though a review of our surgical specimens showed that four lesions had only microinvasion ( 0.1 mm in depth). If 'invasion' is Mammography follow-up for 2.5 years or longer FA: fibroadenoma, DH: ductal hyperplasia, FN: fat necrosis, SA: sclerosing adenosis, FCC: fibrocystic change, ADH: atypical ductal hyperplasia, ALH: atypical lobular hyperplasia, PT: phyllodes tumor, IDC: infiltrating duct carcinoma, LCIS: lobular carcinoma in situ considered to be >2 mm, the rate of the invasive carcinoma would be reduced to 50% of DCIS, as determined at US CNB. Another possible cause of the higher prevalence of invasive carcinoma recovery may be the smaller number (average, five) of cores obtained per solid mass lesion visualized at US, as compared to the average number of cores in stereotactic CNB (five per mass lesion and ten per microcalcification). When DCIS without invasive carcinoma is diagnosed at CNB, further histologic evaluation by excisional biopsy is, therefore, required.
Second, with regard to atypical hyperplasia, previous reports have addressed the significance of finding ADH at 14-gauge CNB of the breast. In our series, 75% of ADH or AH diagnosed at US 18-gauge CNB were found to be carcinomas, a prevalence consistent with those previously reported (range, 31 88%; mean, 49%) (17, 19, 20, 23, 26 29) .
There are two potential explanations for the high incidence of discordance between CNB and surgical findings for ADH lesions diagnosed at CNB. First, ADH is a histopathologic entity that meets some but not all of the morphologic criteria for DCIS (a diameter of less than 2 mm or involvement of less than two ducts, for example); because of the small size of CNB, the specimens obtained might not, however, satisfy these quantitative criteria. Second, because of the heterogeneity of breast lesions, ADH may be within or near an associated DCIS.
Reported differences in the prevalence of carcinoma in surgical specimens of lesions identified as ADH at CNB may relate to the size of needle used and the number of cores obtained. It has been noted that increasing the number of cores per lesion reduced both the number of ADHs diagnosed at CNB and subsequent histologic discordance with the findings of excisional biopsy (4) . For a given number of cores, histopathologic diagnosis is more likely for masses than for lesions with microcalcification (30); most radiologists now accept that for nodules or densities, a minimum of five cores should be obtained, and for microcalcifications a minimum of ten.
Studies have suggested that better results were obtained with 14-gauge needles than with 18-gauge, particularly for biopsy of microcalcifications (13, 30) . Fourteen-gauge needles were used in those studies, while we used 18-gauge only. These aim at reducing possible complications, including local hemorrhage, discomfort and tumor seeding along the needle track, the risk of which, according to reports (31 33) , correlates with the gauge of needle used. There is, however, some degree of controversy and doubt as to whether larger needles are as harmless as smaller ones, and whether they cause prohibitive amounts of bleeding (9 11) . For this reason, and because of the possible limitations of large-core breast biopsy, some investigators advocate the use of smaller needles. Accordingly, it seems that a comparison between 18-gauge and other needles in terms of their precise reliability would be meaningful.
The target of ultrasound is solid masses that require smaller needles and fewer cores for histologic diagnosis of the same accuracy. Our data indicate that for the diagnosis of ADH at US CNB, an 18-gauge needle and five cores are suitable; as indicated by earlier studies of stereotactic CNB with findings of ADH, excisional biopsy is necessary.
Third, with regard to fibroepithelial lesions, two of 31 fibroadenomas in our series, diagnosed at US CNB were found at examination of surgical specimens to be phyllodes tumors. One was low grade, with an extensive benign hyalinized component, and the other was benign. In core-needle specimens, the fibrotic stroma was predominant and the focal leaf-like pattern was overlooked. In most situations, such as the present study and a previous report (34) , CNB can be used to distinguish a phyllodes tumor from a fibroadenoma, but heterogeneity within a lesion means that more reliable diagnosis is likely to require a larger tissue sample (13) .
Examination of surgical specimens showed that five fibroepithelial lesions diagnosed at US CNB were four phyllodes tumors and one fibroadenoma. Two of PTs were low grade, and two were benign.
In cases of epithelial lesions where diagnosis differs between CNB and the clinical or radiological findings, either excisional biopsy or close follow-up, clinically and radiologically, is, therefore, required.
In summary, US CNB using an 18-gauge needle is a safe and reliable means of diagnosing breast carcinoma in which the findings of ultrasonography are positive. Diagnostic accuracy is comparable to that of excisional biopsy. Because of the high prevalence of ductal/lobular carcinoma in such lesions, US CNB findings of ADH/ AH and lobular neoplasia indicate that surgical excision is required.
The use of US CNB can avoid many unnecessary open biopsies for benign lesions, while discordance between CNB diagnosis and the clinical and/or radiological findings requires close follow-up or excisional biopsy. Our data indicate that for non-palpable solid breast lesions, the overall diagnostic accuracy of US 18-gauge CNB is comparable to that of standard stereotactic CNB using 14-gauge needles.
